Adaptive Biotechnologies CSO Robins sells $799k in ADPT stock By Investing.com
Adaptive Biotechnologies' Chief Scientific Officer, Harlan S. Robins, sold 42,788 shares of ADPT stock for approximately $799,104 across February 2nd and 3rd, 2026. These sales were executed near the company's 52-week high, following an impressive 114.91% return over the past year for ADPT shares, currently trading at $17.30. The company reported strong financial results for 2025, with revenue increases and strategic partnerships, leading Piper Sandler to reiterate an Overweight rating.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Adaptive Biotechnologies (NASDAQ:ADPT) exceeded analyst expectations for its full-year results, with revenues of US$277m and statutory losses of US$0.39 per share, both better than anticipated. Following these results, analysts have updated their 2026 forecasts, predicting revenues of US$277.2m and a 28% increase in losses to US$0.49 per share, marking a noticeable increase in sentiment despite no change to the consensus price target. The company's projected revenue growth of 0.09% annually until 2026 is significantly lower than its historical 12% p.a. over the last five years and also slower than its industry peers.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q4 2025 Earnings Call Transcript
Adaptive Biotechnologies (NASDAQ:ADPT) reported strong financial results for Q4 and full-year 2025, with total revenue growing 55% year-over-year. The company's MRD business achieved profitability ahead of expectations, with revenue up 46%, driven by increased clonoSEQ test volumes and ASP expansion. Adaptive also highlighted progress in its Immune Medicine business through data partnerships and strategic focus on AI modeling, projecting positive adjusted EBITDA and free cash flow for the entire company by the end of 2026.
Adeptus Biotechnologies stock price target raised to $22 by BTIG on strong MRD growth
BTIG has raised its price target for Adeptus Biotechnologies (NASDAQ:ADPT) to $22.00 from $21.00, maintaining a Buy rating. This adjustment follows the company's robust growth in its Minimal Residual Disease (MRD) business, which saw a 54% year-over-year increase in Q4 2025 and 46% for the full year. The company also exceeded analyst expectations for Q4 2025 earnings and revenue, reporting an EPS of -$0.09 and revenue of $71.7 million.
Adaptive Biotechnologies CSO Robins sells $799k in ADPT stock By Investing.com
Adaptive Biotechnologies' Chief Scientific Officer, Harlan S. Robins, sold 42,788 shares of ADPT stock for approximately $799,104 across February 2nd and 3rd, 2026. These sales, executed via a Rule 10b5-1 trading plan, occurred when the stock was near its 52-week high, with InvestingPro suggesting it might be trading above its Fair Value. The company recently reported strong 2025 financial results with significant revenue growth and strategic agreements, and Piper Sandler reiterated an Overweight rating.
Adaptive Biotechnologies CSO Robins sells $799k in ADPT stock
Adaptive Biotechnologies' Chief Scientific Officer, Harlan S. Robins, sold 42,788 shares of ADPT stock for approximately $799,104, executed through a Rule 10b5-1 trading plan. The sales occurred while ADPT shares have seen a significant 114.91% return over the past year and were near the company's 52-week high. This insider transaction follows Adaptive Biotechnologies reporting robust 2025 financial results and strategic agreements with Pfizer.
Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Misses Revenue Estimates
Adaptive Biotechnologies (ADPT) reported a Q4 loss of $0.09 per share, exceeding the Zacks Consensus Estimate for a loss of $0.19. Despite this, the company missed revenue estimates, posting $71.68 million against an estimated higher figure. The stock's future performance will largely depend on management's outlook, with a current Zacks Rank #3 (Hold) indicating market-aligned performance expectations.
Adaptive Biotechnologies soars after beating Q4 expectations By Investing.com
Adaptive Biotechnologies (NASDAQ:ADPT) significantly exceeded Q4 analyst expectations, reporting a loss of $0.09 per share against an estimated $0.18 loss, with revenue jumping 51% to $71.7 million, well above the $59.33 million consensus. The company's MRD business, which accounted for 86% of quarterly revenue, grew 54%. Adaptive Biotechnologies also achieved positive Adjusted EBITDA of $4.1 million for the quarter and projects 2026 MRD business revenue between $255 million and $265 million.
Adaptive Biotechnologies soars after beating Q4 expectations
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) saw its shares surge over 6% after reporting significantly better-than-expected fourth-quarter results and full-year performance for 2025. The biotechnology company posted a smaller loss per share and substantially higher revenue, driven largely by its MRD business. It also provided an optimistic revenue forecast for its MRD business in 2026 and highlighted key operational achievements.
Earnings call transcript: Adaptive Biotechnologies beats Q4 2025 expectations
Adaptive Biotechnologies (ADPT) reported strong Q4 2025 results, significantly beating EPS and revenue expectations. Despite this, the stock declined in aftermarket trading. The company provided optimistic guidance for 2026, forecasting continued revenue growth and aiming for positive adjusted EBITDA by the end of the year, driven by its MRD business and strategic initiatives.
Adaptive Biotechnologies earnings beat by $0.09, revenue topped estimates
Adaptive Biotechnologies (NASDAQ: ADPT) reported strong fourth-quarter results, beating analyst estimates for both EPS and revenue. The company's EPS came in at $-0.090, outperforming the $-0.180 estimate, and revenue reached $71.7M against an estimated $59.33M. The stock has shown significant growth, rising 11.360% in the last three months and 105.620% over the past year.
Adaptive Biotechnologies (ADPT) falls 24.5% as execs dispose millions of stake
Adaptive Biotechnologies (ADPT) stock experienced a significant 24.5% drop following reports of executive insider selling. Multiple executives, including the CEO, CFO, and COO, disposed of shares totaling millions of dollars. This substantial insider selling activity has raised concerns among investors and is seen as a primary factor for the stock's sharp decline.
Biotech Adaptive Biotechnologies lifts 2025 revenue 55%, narrows loss
Adaptive Biotechnologies (ADPT) reported strong financial results for 2025, with full-year revenue increasing by 55% to $277.0 million. The company's Minimal Residual Disease (MRD) business was a key growth driver, achieving positive Adjusted EBITDA and cash flow. Despite a narrowed net loss, operating expenses remained high, and the company provided MRD revenue guidance for 2026 but no guidance for its Immune Medicine business.
Adaptive Biotechnologies earnings on deck: Path to profitability in focus By Investing.com
Adaptive Biotechnologies is set to release its fourth-quarter and full-year 2025 results, with investor attention keenly focused on the company's projected path to profitability in 2026. Analysts anticipate an earnings per share loss of ($0.18) and revenue of $59.3830 million for the quarter. Key areas of focus for investors include minimal residual disease testing volume growth, management's guidance on operating leverage, and the company's ability to maintain market share against increasing competition.
Adaptive Biotechnologies Executives Sell Shares
Chad M Robins, CEO and Chairman of Adaptive Biotechnologies Corp, sold 124,998 shares of common stock for over $2.3 million on February 2, 2026. Harlan S. Robins, Chief Scientific Officer, also sold 42,788 shares for nearly $800,000 on February 2 and 3, 2026. Both sales were executed under Rule 10b5-1 trading plans adopted in August 2025.
Adaptive Biotechnologies: Fourth Quarter Financial Highlights
Adaptive Biotechnologies Corp. reported a net loss of $13.6 million, or 9 cents per share, for the fourth quarter, which was better than analysts' projected loss of 19 cents per share. The biotechnology firm generated $71.7 million in revenue for the quarter. For the full year, the company reduced its net loss to $59.5 million and achieved $277 million in total annual revenue.
Adaptive Biotechnologies CSO Robins sells $799k in ADPT stock By Investing.com
Adaptive Biotechnologies' Chief Scientific Officer, Harlan S. Robins, sold 42,788 shares of ADPT stock for approximately $799,104 across two dates in early February 2026. These sales, executed under a Rule 10b5-1 trading plan, occurred while the company's shares had seen a significant 114.91% return over the past year and were trading near their 52-week high. The article also notes Adaptive Biotechnologies' strong financial performance in 2025, including a 55% increase in total revenue and strategic agreements with Pfizer.
Chad Robins Sells 124,998 Shares of Adaptive Biotechnologies Corp
Chad Robins, CEO and Chairman of Adaptive Biotechnologies Corp (ADPT), sold 124,998 shares on February 2, 2026. This transaction follows a pattern of insider selling, with Robins having sold over 1.4 million shares in the past year, while there have been no insider buys. The stock is currently trading at $18.44, yet its GF Value is $8.59, indicating that it is significantly overvalued.
Insider Sell: Harlan Robins Sells 42,788 Shares of Adaptive Biotechnologies Corp (ADPT)
Harlan Robins, Chief Scientific Officer of Adaptive Biotechnologies Corp (ADPT), sold 42,788 shares of the company on February 3, 2026, and now owns 1,179,524 shares. Over the past year, Robins has sold a total of 266,766 shares, with no purchases. The stock is considered significantly overvalued with a price-to-GF-Value ratio of 2.17, based on a trading price of $18.68 and a GF Value of $8.59.
Adaptive Biotechnologies (ADPT) falls 24.5% as execs dispose millions of stake
Adaptive Biotechnologies (ADPT) stock experienced a significant 24.5% drop. This decline coincided with company executives disposing of millions of dollars worth of their stake in the company. The article suggests this insider selling activity may have contributed to the stock's downturn.
Biotech using immune genetics schedules Feb. and March investor webcasts
Adaptive Biotechnologies (NASDAQ: ADPT) announced its participation in two upcoming investor conferences. The company will attend the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in February and the TD Cowen 46th Annual Health Care Conference in March, where it will host a fireside chat. Webcasts for both events will be available on the company's investor relations website.
Hear Adaptive Biotechnologies' 2025 results live on Feb. 5
Adaptive Biotechnologies (NASDAQ: ADPT) is scheduled to report its fourth quarter and full year 2025 financial results after market close on Thursday, February 5, 2026. Management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET, accessible via the company's Investors website. The announcement follows strong preliminary Q4 and FY2025 results and strategic partnerships, including with Pfizer.
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026
Adaptive Biotechnologies (Nasdaq: ADPT) announced it will report its financial results for the fourth quarter and full year 2025 after market close on Thursday, February 5, 2026. The company will also host a conference call and webcast at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time for management to discuss the results. The webcast will be available on the company's investor relations website and archived for replay.
Adaptive Biotechnologies Insider Sold Shares Worth $1,411,131, According to a Recent SEC Filing
An insider at Adaptive Biotechnologies Corporation sold shares valued at $1,411,131, as reported in a recent SEC filing. The company is a commercial-stage biotechnology firm focused on leveraging the adaptive immune system for disease diagnosis and treatment. Its business areas include clinical assessment of minimal residual disease (MRD) and immune medicine-driven drug discovery.
Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results
Adaptive Biotechnologies (Nasdaq: ADPT) announced preliminary, unaudited results for Q4 and full year 2025, reporting total revenue of approximately $72 million and $277 million, respectively, representing significant increases over 2024. The company saw strong growth in its MRD business, with clonoSEQ® testing volume increasing 39% for the full year. Adaptive Biotechnologies plans to release its complete financial results in February 2026, anticipating continued leadership in MRD testing and expanded profitability.
Adaptive Biotechnologies CFO Piskel sells $77,220 in shares
Adaptive Biotechnologies CFO Kyle Piskel sold 4,290 shares of common stock for $77,220 on January 12, 2026, after exercising options for the same number of shares. This transaction occurred amidst a significant surge in ADPT shares over the past year. Despite the stock trading above its Fair Value and the company being unprofitable, analysts maintain a Buy consensus, and Adaptive Biotechnologies reported strong revenue growth and strategic agreements.
Adaptive Biotechnologies’ Lo Francis sells $1.4m in shares By Investing.com
Adaptive Biotechnologies' Chief People Officer, Francis Lo, sold 79,590 shares for $1.41 million on January 12, 2026, while also exercising options to acquire an equivalent number of shares. This transaction follows a significant 152% surge in ADPT shares over the past year. Despite the company appearing overvalued by InvestingPro, analysts maintain a "Strong Buy" recommendation on the stock.
Adaptive Biotechnologies’ Lo Francis sells $1.4m in shares
Adaptive Biotechnologies' Chief People Officer, Francis Lo, sold 79,590 shares of the company's common stock for $1.41 million, following exercising options for an equal number of shares. The company has seen significant stock growth, 152% over the past year, and analysts maintain a "Strong Buy" recommendation despite the stock appearing overvalued by some metrics. Adaptive Biotechnologies also reported a 55% revenue increase in 2025 and announced strategic agreements and partnerships.
Adaptive Biotechnologies Exec Sells Shares
Francis Lo, Chief People Officer at Adaptive Biotechnologies Corp (ADPT), sold 79,590 shares of common stock on January 12, 2026, for a total of $1,411,130. The transaction was conducted under a Rule 10b5-1 trading plan. Following the sale, Lo directly owns 315,978 shares and indirectly owns 2,500 shares.
Assessing Adaptive Biotechnologies (ADPT) Valuation After Strong Recent Share Price Momentum
Adaptive Biotechnologies (ADPT) has seen significant recent share price momentum, with its stock currently trading at $18.07. Despite strong short-term returns and a narrative valuation suggesting the stock is 7.7% undervalued at $19.57 per share, its 10.9x Price/Sales ratio is considerably higher than the industry average, raising questions about execution risk. The narrative emphasizes the company's cancer testing franchise and growing clinical trial backlog, but also points out the current net loss and reliance on partnerships.
Piper Sandler reiterates Overweight rating on Adeptus Biotechnologies stock
Piper Sandler has reiterated an Overweight rating and a $20.00 price target for Adeptus Biotechnologies (NASDAQ:ADPT) after the company's presentation at a competitor's conference. The firm highlighted Adeptus Biotechnologies' projection for 2026 to be a landmark financial year, expecting positive adjusted EBITDA and free cash flow. The company also anticipates over 30% growth in clinical volumes for its Minimal Residual Disease (MRD) business, which is expected to drive profitability.
Adaptive Biotechnologies Corp (ADPT) Stock Analysis: Revenue Growth Surges Over 100%, Analysts Eye 9.53% Upside
Adaptive Biotechnologies Corporation (ADPT) is drawing investor attention due to its substantial revenue growth of 102.40% and positive analyst outlook. Despite current financial challenges like negative EPS and ROI, the company maintains robust free cash flow and strong bullish technical indicators. Analysts predict a potential upside of 9.53%, highlighting ADPT's innovative immune medicine platform and strategic collaborations as key drivers for long-term growth.
Adaptive Biotechnologies Touts clonoSEQ MRD Growth, Targets Companywide Profitability in 2026
Adaptive Biotechnologies highlighted the significant growth of its clonoSEQ minimal residual disease (MRD) franchise and outlined a strategy for its immune medicine (IM) unit at the J.P. Morgan healthcare conference. The company reiterated its expectation to achieve companywide profitability, specifically positive adjusted EBITDA and positive free cash flow, in 2026. clonoSEQ is now a substantial business exceeding $200 million, with robust clinical revenue growth and expanding patient adoption.
Adaptive Biotechnologies' Q4 Preliminary Revenue Rises 51%; Shares Jump in Premarket Trading
Adaptive Biotechnologies announced preliminary Q4 2025 revenue rose by 51%, leading to a jump in its shares during premarket trading. The company also announced preliminary full-year 2025 results. This positive news follows several recent insider transactions and licensing agreements, including two immune receptor licensing deals with Pfizer.
Adaptive Biotechnologies (ADPT) Surpasses Q4 Revenue Estimates, Shares Climb
Adaptive Biotechnologies (ADPT) significantly exceeded its preliminary Q4 2025 revenue estimates, reporting $72 million against a projected $59.4 million, leading to a 12.6% increase in premarket trading. The company also reported strong full-year revenues of $277 million and a healthy cash reserves of $227 million. Despite robust revenue growth, ADPT faces profitability challenges and high volatility, but its strong balance sheet and analyst "Buy" consensus offer a positive outlook.
Adaptive Biotechnologies Reports Preliminary Financial Results for Q4 and Full Year 2025, Highlighting Significant Revenue Growth
Adaptive Biotechnologies announced strong preliminary financial results for Q4 and full year 2025, with total revenues of approximately $72 million and $277 million, respectively, marking significant increases over 2024. Minimal Residual Disease (MRD) revenue and clonoSEQ test volumes also experienced substantial growth. The company anticipates releasing finalized financial results, with profitability expected to improve, in February 2026.
Adaptive Biotechnologies reports 55% revenue growth in 2025
Adaptive Biotechnologies reported strong preliminary financial results for 2025, with total revenue increasing by 55% to $277 million for the full year and 51% for the fourth quarter. The company's clonoSEQ product also saw significant growth, with a 39% increase in tests delivered for the full year. These figures, along with recent strategic agreements and financing efforts, underscore the company's robust performance and market position.
Insider Sell: Harlan Robins Sells Shares of Adaptive Biotechnolo
Harlan Robins, Chief Scientific Officer at Adaptive Biotechnologies Corp (ADPT), sold 10,000 shares of the company on January 6, 2026, bringing his total ownership to 1,222,312 shares. This transaction follows a pattern of 31 insider sells and no insider buys at Adaptive Biotechnologies Corp over the past year. The company's stock is currently trading at $16.44, which is significantly overvalued compared to its GF Value estimate of $8.59.
Adaptive Biotechnologies CSO Robins sells $164k in shares
Harlan S. Robins, Chief Scientific Officer of Adaptive Biotechnologies Corp (NASDAQ:ADPT), sold 10,000 shares of common stock for $164,400. This sale was executed under a pre-arranged Rule 10b5-1 trading plan. The company has shown strong revenue growth and is nearing its 52-week high, despite not yet achieving profitability.
Adaptive Biotechnologies spinout raising $15M to develop clinical sequencing tech
Digital Biotechnologies Inc., a Seattle-based spinout of Adaptive Biotechnologies, is raising up to $15 million in Series A funding to develop clinical sequencing technology. The company aims to create a solid-state sequencer capable of high accuracy, rapid turnaround, and low cost for widespread clinical applications, leveraging Adaptive's expertise. Adaptive Biotechnologies will retain nearly half ownership of the spinout and will consolidate its financial results.
Chad Robins Sells 124,998 Shares of Adaptive Biotechnologies Cor
Chad Robins, CEO and Chairman of Adaptive Biotechnologies Corp (ADPT), sold 124,998 shares on January 5, 2026, reducing his holding to 2,584,243 shares. Over the past year, Robins has sold a total of 1,350,121 shares with no purchases. The stock, trading at $15.59, appears significantly overvalued with a price-to-GF-Value ratio of 1.81, based on GuruFocus's intrinsic value estimate of $8.59.
Adaptive Biotechnologies’ Lo Francis sells $76,895 in shares
Francis Lo, Chief People Officer at Adaptive Biotechnologies Corp, sold 4,394 shares for $76,895 and also exercised options to acquire the same number of shares for $26,640. These transactions occurred near the stock's 52-week high, with the company also announcing new financing for a subsidiary and two non-exclusive agreements with Pfizer Inc. for T-cell receptor discovery and immune data licensing.
Adaptive Biotechnologies Corporation (ADPT) Stock Analysis: Unraveling Its 22.8% Potential Upside
Adaptive Biotechnologies Corporation (ADPT) shows promising prospects for investors with a potential upside of 22.80%, driven by its innovative immune medicine platform and impressive revenue growth of 102.40%. Despite a negative P/E ratio and return on equity, the company benefits from strategic collaborations like the one with Genentech and positive analyst ratings, with seven buy ratings and a consensus target price indicating significant growth. The biotech firm's focus on groundbreaking T cell therapies and diagnostic tests for cancer underscores its commitment to research and development, making it an attractive stock for growth-oriented portfolios.
Adaptive Biotechnologies discloses it's raising $15 million for subsidiary
Adaptive Biotechnologies is raising $15 million for one of its subsidiaries, a move that will dilute the Seattle company's ownership in the subsidiary from 70% to less than 50%. The company, founded in 2009, went public in 2019. This capital raise signals a strategic shift in the financial structure of its subsidiary.
Adaptive Biotechnologies announces subsidiary’s Series A financing round
Adaptive Biotechnologies Corp (NASDAQ:ADPT) announced that its 70%-owned subsidiary, Digital Biotechnologies, Inc., has commenced a Series A Preferred Stock financing round aiming to raise up to $15 million. Adaptive Biotechnologies expects to retain nearly a 50% ownership interest in Digital Biotechnologies after the financing and consolidate its results. This announcement follows strong Q3 2025 financial results for Adaptive Biotechnologies and recent non-exclusive agreements with Pfizer.
Adaptive Biotechnologies announces subsidiary’s Series A financing round By Investing.com
Adaptive Biotechnologies announced that its 70%-owned subsidiary, Digital Biotechnologies, Inc., has commenced a Series A Preferred Stock financing round with anticipated proceeds of up to $15 million. Adaptive expects to maintain nearly 50% ownership and continue consolidating Digital Biotechnologies' financial results. This development follows strong Q3 2025 financial performance, strategic partnerships with Pfizer, and an "Overweight" rating from Piper Sandler despite increased market competition.
Adaptive Biotechnologies to Present at the 44th Annual J.P. Morgan Healthcare Conference
Adaptive Biotechnologies Corporation announced its participation in the 44th Annual J.P. Morgan Healthcare Conference, where its management is scheduled to present on January 12, 2026. The company, a commercial-stage biotechnology firm, focuses on leveraging the adaptive immune system for diagnosing and treating diseases, with a platform used for partnerships, drug development, and clinical diagnostics. A webcast of the presentation will be available for interested parties on the company's investor relations website.
Adaptive Biotechnologies Announces Series A Financing for Subsidiary
Adaptive Biotechnologies announced a Series A financing round for its subsidiary, Digital Biotechnologies, with an initial closing achieved. The round is expected to generate up to $15 million in proceeds, and Adaptive Biotechnologies anticipates retaining nearly 50% ownership while consolidating Digital Biotechnologies' results into its own financials.
Adaptive biotechnologies CPO Lo sells $76,895 in ADPT stock
Francis Lo, Chief People Officer at Adaptive Biotechnologies Corp (NASDAQ:ADPT), sold 4,394 shares of common stock for approximately $76,895 and exercised options to acquire the same number of shares. The company has shown significant growth with a 178.57% year-to-date return and strong revenue growth. Adaptive Biotechnologies also reported a strong Q3 2025 performance and announced non-exclusive agreements with Pfizer.
Adaptive Biotechnologies (ADPT): Valuation Check After New Pfizer T-Cell Discovery and AI Drug Collaboration Deals
Adaptive Biotechnologies (ADPT) has recently secured two non-exclusive deals with Pfizer, focusing on T-cell receptor discovery and AI-driven drug discovery for rheumatoid arthritis. This follows a significant rerating for ADPT, with a 181% year-to-date share price return. While a "narrative" valuation suggests the stock is 11% undervalued, a "revenue multiples" perspective indicates it is currently overvalued compared to industry peers.
